4 reports of this reaction
1.8% of all VARDENAFIL HYDROCHLORIDE reports
#7 most reported adverse reaction
DYSCHROMATOPSIA is the #7 most commonly reported adverse reaction for VARDENAFIL HYDROCHLORIDE, manufactured by Alembic Pharmaceuticals Inc.. There are 4 FDA adverse event reports linking VARDENAFIL HYDROCHLORIDE to DYSCHROMATOPSIA. This represents approximately 1.8% of all 218 adverse event reports for this drug.
Patients taking VARDENAFIL HYDROCHLORIDE who experience dyschromatopsia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSCHROMATOPSIA is a less commonly reported adverse event for VARDENAFIL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dyschromatopsia, the following adverse reactions have been reported for VARDENAFIL HYDROCHLORIDE:
DYSCHROMATOPSIA has been reported as an adverse event in 4 FDA reports for VARDENAFIL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSCHROMATOPSIA accounts for approximately 1.8% of all adverse event reports for VARDENAFIL HYDROCHLORIDE, making it a notable side effect.
If you experience dyschromatopsia while taking VARDENAFIL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.